Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALRNNASDAQ:APMNASDAQ:CYCNNASDAQ:MEDS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALRNAileron Therapeutics$2.52$1.61▼$4.40$45.72M2.2486,102 shs63,385 shsAPMAptorum Group$1.04-4.6%$0.96$0.46▼$7.49$5.56M-0.14619,192 shs18,267 shsCYCNCyclerion Therapeutics$3.15+1.3%$3.06$1.27▼$9.47$10.11M1.581.28 million shs3,302 shsMEDSTRxADE HEALTH$0.99+3.6%$0.94$3.69▼$44.56$1.40M2.32207,831 shs55,346 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALRNAileron Therapeutics0.00%0.00%0.00%0.00%-32.37%APMAptorum Group-4.58%-4.59%+13.03%+10.99%-76.89%CYCNCyclerion Therapeutics+1.29%+0.80%+1.29%+16.24%+40.00%MEDSTRxADE HEALTH-10.24%-16.52%+7.74%-49.47%-90.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALRNAileron TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAPMAptorum Group0.5128 of 5 stars0.03.00.00.00.61.70.6CYCNCyclerion Therapeutics0.7625 of 5 stars0.03.00.00.00.03.30.6MEDSTRxADE HEALTHN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALRNAileron Therapeutics 0.00N/AN/AN/AAPMAptorum Group 0.00N/AN/AN/ACYCNCyclerion Therapeutics 0.00N/AN/AN/AMEDSTRxADE HEALTH 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALRNAileron TherapeuticsN/AN/AN/AN/A$1.41 per shareN/AAPMAptorum Group$430K12.94N/AN/A$2.20 per share0.47CYCNCyclerion Therapeutics$2M5.06N/AN/A$3.27 per share0.96MEDSTRxADE HEALTH$7.45M0.19N/AN/A$0.45 per share2.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALRNAileron Therapeutics-$15.73M-$3.120.00N/AN/AN/A-74.08%-27.93%N/AAPMAptorum Group-$4.27MN/A0.00∞N/AN/AN/AN/A7/30/2025 (Estimated)CYCNCyclerion Therapeutics-$3.06M-$1.16N/A∞N/AN/A-34.02%-30.68%8/6/2025 (Estimated)MEDSTRxADE HEALTH-$17.84MN/A0.00∞N/A-149.81%-196.79%-112.21%6/24/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALRNAileron TherapeuticsN/AN/AN/AN/AN/AAPMAptorum GroupN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AMEDSTRxADE HEALTHN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALRNAileron TherapeuticsN/A3.303.30APMAptorum GroupN/A0.220.22CYCNCyclerion TherapeuticsN/A4.214.21MEDSTRxADE HEALTHN/A4.184.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALRNAileron Therapeutics90.89%APMAptorum Group3.80%CYCNCyclerion Therapeutics75.62%MEDSTRxADE HEALTH5.68%Insider OwnershipCompanyInsider OwnershipALRNAileron Therapeutics5.10%APMAptorum Group63.99%CYCNCyclerion Therapeutics34.30%MEDSTRxADE HEALTH48.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALRNAileron Therapeutics921.67 million20.56 millionNot OptionableAPMAptorum Group305.35 million1.93 millionNot OptionableCYCNCyclerion Therapeutics303.21 million2.11 millionNo DataMEDSTRxADE HEALTH501.41 million725,000Not OptionableMEDS, CYCN, APM, and ALRN HeadlinesRecent News About These CompaniesWellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder ValueMay 28, 2025 | accessnewswire.comOragenics gears up for Phase II trials, appoints new CEOJanuary 21, 2025 | msn.comTRxADE Health (NASDAQ: MEDS)November 23, 2024 | fool.comScienture Holdings, Inc. (SCNX)November 15, 2024 | finance.yahoo.comTravis County extends opioid public health crisis declarationNovember 13, 2024 | msn.comMedicaid covers GLP-1 meds for obesity in just 13 states, analysis findsNovember 5, 2024 | medicalxpress.comYou Can Now Get Prescription Weight Loss Drugs Like Ozempic From An Online Telehealth Visit. But Is It Safe?November 5, 2024 | msn.comADHD drugs' impact on brain health, quality of life: What we knowOctober 31, 2024 | medicalnewstoday.comUS releases preliminary list of $2 generic drugs for Medicare recipientsOctober 11, 2024 | reuters.comMedications increase risk for heat-related illnesses during extended heat waveOctober 11, 2024 | msn.comHarvard Health Ad Watch: Got side effects? There's a medicine for thatOctober 11, 2024 | msn.comCMS releases RFI, sample list of prescription drugs that may be included under proposed Medicare $2 Drug List ModelOctober 11, 2024 | aha.orgThe end of a shortage of popular weight-loss drugs may mean many people lose access to themOctober 11, 2024 | msn.comWeight-loss drugs are life-changing — and expensive. Here's one woman's solution.September 27, 2024 | aol.comOlder migraine drugs more effective than some newer options, study findsSeptember 25, 2024 | medicalnewstoday.comGoogle trends reveals surge in ADHD medication searches during COVID-19 pandemicSeptember 24, 2024 | medicalxpress.comScienture Holdings Inc (SCNX)September 24, 2024 | sg.finance.yahoo.comTRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”September 24, 2024 | markets.businessinsider.comTriptans better at relieving migraine pain than recently marketed and more expensive drugsSeptember 23, 2024 | news-medical.netTypes of Medications for Heart Attack Prevention and TreatmentSeptember 21, 2024 | verywellhealth.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMEDS, CYCN, APM, and ALRN Company DescriptionsAileron Therapeutics NASDAQ:ALRNAileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.Aptorum Group NASDAQ:APM$1.04 -0.05 (-4.59%) Closing price 06/18/2025 03:58 PM EasternExtended Trading$1.06 +0.02 (+2.31%) As of 06/18/2025 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.Cyclerion Therapeutics NASDAQ:CYCN$3.15 +0.04 (+1.29%) Closing price 06/18/2025 03:52 PM EasternExtended Trading$3.13 -0.02 (-0.60%) As of 06/18/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.TRxADE HEALTH NASDAQ:MEDS$0.99 +0.03 (+3.64%) As of 06/18/2025TRxADE HEALTH, Inc. operates as a health services information technology (IT) company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement; and designs, develops, owns, and operates a business-to-business web-based marketplace. It also distributes prescription medication, medical devices, and over the counter medication to pharmacies and medical clinics; and offers pricing transparency, purchasing capabilities, and other value-added services, as well as telehealth services. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. was founded in 2010 and is headquartered in Lutz, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
